Exact Mass: 333.1056278
Exact Mass Matches: 333.1056278
Found 464 metabolites which its exact mass value is equals to given mass value 333.1056278,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Dihydrosanguinarine
C20H15NO4 (333.10010300000005)
Dihydrosanguinarine is a benzophenanthridine alkaloid obtained by selective hydrogenation of the 13,14-position of sanguinarine. It has a role as a metabolite and an antifungal agent. It derives from a hydride of a sanguinarine. Dihydrosanguinarine is a natural product found in Sarcocapnos baetica, Sarcocapnos saetabensis, and other organisms with data available. A benzophenanthridine alkaloid obtained by selective hydrogenation of the 13,14-position of sanguinarine. Dihydrosanguinarine is a natural compound isolated from the leaves of Macleaya microcarpa; has antifungal and anticancer activity. IC50 value: Target: in vitro: Dihydrosanguinarine showed much less cytotoxicity than sanguinarine: at the highest concentration tested (20 microM) and 24h exposure, dihydrosanguinarine decreased viability only to 52\\% [1]. Dihydrosanguinarine showed the highest antifungal activity against B. cinerea Pers, with 95.16\\% mycelial growth inhibition at 50 μg/ml [2]. dihydrosanguinarine showed the most potent leishmanicidal activities (IC(50) value: 0.014 microg/ml, respectively) [4]. in vivo: Repeated dosing of DHSG for 90 days at up to 500 ppm in the diet (i.e. approximately 58 mg/kg/day) showed no evidence of toxicity in contrast to results published in the literature [3]. Dihydrosanguinarine is a natural compound isolated from the leaves of Macleaya microcarpa; has antifungal and anticancer activity. IC50 value: Target: in vitro: Dihydrosanguinarine showed much less cytotoxicity than sanguinarine: at the highest concentration tested (20 microM) and 24h exposure, dihydrosanguinarine decreased viability only to 52\% [1]. Dihydrosanguinarine showed the highest antifungal activity against B. cinerea Pers, with 95.16\% mycelial growth inhibition at 50 μg/ml [2]. dihydrosanguinarine showed the most potent leishmanicidal activities (IC(50) value: 0.014 microg/ml, respectively) [4]. in vivo: Repeated dosing of DHSG for 90 days at up to 500 ppm in the diet (i.e. approximately 58 mg/kg/day) showed no evidence of toxicity in contrast to results published in the literature [3].
Norchelerythrine
C20H15NO4 (333.10010300000005)
Norchelerythrine is a benzophenanthridine alkaloid. Norchelerythrine is a natural product found in Zanthoxylum beecheyanum, Zanthoxylum scandens, and other organisms with data available. D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents D000970 - Antineoplastic Agents
Pirimiphosethyl
CONFIDENCE standard compound; INTERNAL_ID 623; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10152; ORIGINAL_PRECURSOR_SCAN_NO 10151 CONFIDENCE standard compound; INTERNAL_ID 623; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10138; ORIGINAL_PRECURSOR_SCAN_NO 10137 CONFIDENCE standard compound; INTERNAL_ID 623; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10202; ORIGINAL_PRECURSOR_SCAN_NO 10201 CONFIDENCE standard compound; INTERNAL_ID 623; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10195; ORIGINAL_PRECURSOR_SCAN_NO 10194 CONFIDENCE standard compound; INTERNAL_ID 623; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10210; ORIGINAL_PRECURSOR_SCAN_NO 10209 CONFIDENCE standard compound; INTERNAL_ID 623; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10096; ORIGINAL_PRECURSOR_SCAN_NO 10095
Ethalfluralin
C13H14F3N3O4 (333.09363600000006)
[(1S)-2-[2-[(2R)-2-amino-2-carboxyethyl]sulfinyl-1H-imidazol-5-yl]-1-carboxyethyl]-trimethylazanium
C12H21N4O5S+ (333.12325960000004)
(11S,14S)-Cyclo-(L-Trp-L-Phe)
A natural product found in Aspergillus sydowii.
3-[(2-Chlorobenzylidene)amino]-6H-dibenzo[b,d]pyran-6-one
Pefloxacin
C17H20FN3O3 (333.14886220000005)
Pefloxacin is only found in individuals that have used or taken this drug. It is a synthetic broad-spectrum fluoroquinolone antibacterial agent active against most gram-negative and gram-positive bacteria. [PubChem]The bactericidal action of pefloxacin results from interference with the activity of the bacterial enzymes DNA gyrase and topoisomerase IV, which are needed for the transcription and replication of bacterial DNA. DNA gyrase appears to be the primary quinolone target for gram-negative bacteria. Topoisomerase IV appears to be the preferential target in gram-positive organisms. Interference with these two topoisomerases results in strand breakage of the bacterial chromosome, supercoiling, and resealing. As a result DNA replication and transcription is inhibited. J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01M - Quinolone antibacterials > J01MA - Fluoroquinolones D004791 - Enzyme Inhibitors > D065607 - Cytochrome P-450 Enzyme Inhibitors > D065609 - Cytochrome P-450 CYP1A2 Inhibitors D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059005 - Topoisomerase II Inhibitors D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D024841 - Fluoroquinolones C254 - Anti-Infective Agent > C258 - Antibiotic > C795 - Quinolone Antibiotic
gamma-Glutamyltryptophan
gamma-Glutamyltryptophan is a dipeptide composed of gamma-glutamate and tryptophan, and is a proteolytic breakdown product of larger proteins. It belongs to the family of N-acyl-alpha amino acids and derivatives. These are compounds containing an alpha amino acid which bears an acyl group at its terminal nitrogen atom. gamma-Glutamyltryptophan is an incomplete breakdown product of protein digestion or protein catabolism. Some dipeptides are known to have physiological or cell-signaling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis.
Glutamyltryptophan
Glutamyltryptophan is a dipeptide composed of glutamate and tryptophan, and is a proteolytic breakdown product of larger proteins. It belongs to the family of N-acyl-alpha amino acids and derivatives. These are compounds containing an alpha amino acid which bears an acyl group at its terminal nitrogen atom. Glutamyltryptophan is an incomplete breakdown product of protein digestion or protein catabolism. Some dipeptides are known to have physiological or cell-signaling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis. Glutamyltryptophan can be found in feces (PMID: 27015276). The synthetic version of this dipeptide is named Oglufanide. It was originally developed to treat severe infectious disease in Russia (where it is a registered pharmaceutical), and was extensively studied in cancer clinical trials in the United States before being acquired by Implicit Bioscience in 2005. Oglufanide works as a regulator of the bodys immune response and is being given by intranasal administration to patients with chronic hepatitis C viral infection (DB05779). C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor C308 - Immunotherapeutic Agent Oglufanide (H-Glu-Trp-OH) is a dipeptide immunomodulator isolated from calf thymus. Oglufanide inhibits vascular endothelial growth factor (VEGF). Oglufanide can stimulate the immune response to hepatitic C virus (HCV) and intracellular bacterial infections. Oglufanide shows antitumor and anti-angiogenesis activities[1][2][3]. Oglufanide (H-Glu-Trp-OH) is a dipeptide immunomodulator isolated from calf thymus. Oglufanide inhibits vascular endothelial growth factor (VEGF). Oglufanide can stimulate the immune response to hepatitic C virus (HCV) and intracellular bacterial infections. Oglufanide shows antitumor and anti-angiogenesis activities[1][2][3].
Tryptophyl-Glutamate
Tryptophyl-Glutamate is a dipeptide composed of tryptophan and glutamate. It is an incomplete breakdown product of protein digestion or protein catabolism. Some dipeptides are known to have physiological or cell-signaling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis. This dipeptide has not yet been identified in human tissues or biofluids and so it is classified as an Expected metabolite.
Bromodiphenhydramine
C17H20BrNO (333.07281700000004)
Bromodiphenhydramine is only found in individuals that have used or taken this drug. It is an ethanolamine antihistamine with antimicrobial property. Bromodiphenhydramine is used in the control of cutaneous allergies. Ethanolamine antihistamines produce marked sedation in most patientsBromodiphenhydramine competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. R - Respiratory system > R06 - Antihistamines for systemic use > R06A - Antihistamines for systemic use > R06AA - Aminoalkyl ethers C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist
2-(4-Nitrophenoxy)-1-(4-phenylphenyl)ethanone
C20H15NO4 (333.10010300000005)
10-Acetoxydecarbamoylmitomycin C
Andolast
C78273 - Agent Affecting Respiratory System > C29712 - Anti-asthmatic Agent > C319 - Bronchodilator
Ciglitazone
C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C98241 - Thiazolidinedione Antidiabetic Agent D007004 - Hypoglycemic Agents
Meglitinide
C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C98079 - Meglitinide Antidiabetic Agent D007004 - Hypoglycemic Agents
Oxonorfloxacin
Flurtamone
CONFIDENCE standard compound; INTERNAL_ID 2318 CONFIDENCE standard compound; INTERNAL_ID 8438 CONFIDENCE standard compound; INTERNAL_ID 4064 CONFIDENCE standard compound; EAWAG_UCHEM_ID 3600 EAWAG_UCHEM_ID 3600; CONFIDENCE standard compound
Tropatepine
N - Nervous system > N04 - Anti-parkinson drugs > N04A - Anticholinergic agents > N04AA - Tertiary amines C78272 - Agent Affecting Nervous System > C38149 - Antiparkinsonian Agent C78272 - Agent Affecting Nervous System > C29698 - Antispasmodic Agent
Epinephrine bitartrate
C13H19NO9 (333.10597640000003)
D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013566 - Sympathomimetics C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D009184 - Mydriatics D002317 - Cardiovascular Agents > D014662 - Vasoconstrictor Agents
7,9-Dimethoxy-2,3-methylendioxybenzophenanthridine
C20H15NO4 (333.10010300000005)
fumimycin
C16H15NO7 (333.08484799999997)
A member of the class of 1-benzofurans that is 1-benzofuran-2(3H)-one substituted by a propenyl group at position 4, hydroxy groups at positions 5 and 6, methyl group at position 3 and a [(2E)-3-carboxyprop-2-enoyl]nitrilo group at position 3. Isolated from the fermentation broth of Aspergillus fumisynnematus F746, it exhibits antibacterial activity.
9-hydroxy-2-nonenoic lactone mercapturic acid
C14H23NO6S (333.12460180000005)
5-methyl-5,6-dihydro[1,3]benzodioxolo[5,6-c][1,3]dioxolo[4,5-j]phenanthridine
C20H15NO4 (333.10010300000005)
N-acetyl-9-O-acetyl-2-deoxy-2,3-didehydroneuraminic acid
C13H19NO9 (333.10597640000003)
cassiarin J|methyl 3-hydroxy-2-methoxy-3-cassiarin A-acetate
5-hydroxy-2-(2-hydroxyethyl)-7-phenyl-1h-benzo[de]isoquinoline-1,6(2h)-dione
C20H15NO4 (333.10010300000005)
Tilivalline
A pyrrolobenzodiazepine that is (11aS)-2,3,5,10,11,11a-hexahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepine substituted by an oxo group at position 5, by a hydroxy group at position 9, and by a 1H-indol-3-yl group at position 11S. It is a natural product discovered in Klebsiella oxytoca which is the causative toxin in antibiotic associated hemorrhagic colitis. It exhibits a microtubule-stabilizing activity that leads to mitotic arrest in the host cells.
7-(3-hydroxy-3-methyl-2-oxo-butyl)-6-methoxy-9-methyl-9H-[1,3]dioxolo[4,5-h]quinolin-8-one|hydroxyisoorixinone|hydroxylunidonine|Hydroxyluzidonin
ciglitazone
C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C98241 - Thiazolidinedione Antidiabetic Agent D007004 - Hypoglycemic Agents
3-benzyl-6-(1H-indol-3-ylmethyl)piperazine-2,5-dione
C16H19N3O5_11-Hydroxy-11-isopropyl-4-methoxy-8-methyl-10,11-dihydro-6H-oxepino[2,3-d]pyrazino[1,2-a]pyrimidine-6,9(8H)-dione
Pefloxacin
C17H20FN3O3 (333.14886220000005)
J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01M - Quinolone antibacterials > J01MA - Fluoroquinolones D004791 - Enzyme Inhibitors > D065607 - Cytochrome P-450 Enzyme Inhibitors > D065609 - Cytochrome P-450 CYP1A2 Inhibitors D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059005 - Topoisomerase II Inhibitors D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D024841 - Fluoroquinolones C254 - Anti-Infective Agent > C258 - Antibiotic > C795 - Quinolone Antibiotic
CI-959
CONFIDENCE standard compound; INTERNAL_ID 1187; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4644; ORIGINAL_PRECURSOR_SCAN_NO 4643 CONFIDENCE standard compound; INTERNAL_ID 1187; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4658; ORIGINAL_PRECURSOR_SCAN_NO 4656 CONFIDENCE standard compound; INTERNAL_ID 1187; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4623; ORIGINAL_PRECURSOR_SCAN_NO 4622 CONFIDENCE standard compound; INTERNAL_ID 1187; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4643; ORIGINAL_PRECURSOR_SCAN_NO 4641 CONFIDENCE standard compound; INTERNAL_ID 1187; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4743; ORIGINAL_PRECURSOR_SCAN_NO 4742 CONFIDENCE standard compound; INTERNAL_ID 1187; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4666; ORIGINAL_PRECURSOR_SCAN_NO 4664 CONFIDENCE standard compound; INTERNAL_ID 1187; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9102; ORIGINAL_PRECURSOR_SCAN_NO 9101 CONFIDENCE standard compound; INTERNAL_ID 1187; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9117; ORIGINAL_PRECURSOR_SCAN_NO 9116 CONFIDENCE standard compound; INTERNAL_ID 1187; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9137; ORIGINAL_PRECURSOR_SCAN_NO 9136 CONFIDENCE standard compound; INTERNAL_ID 1187; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9164; ORIGINAL_PRECURSOR_SCAN_NO 9162 CONFIDENCE standard compound; INTERNAL_ID 1187; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9184; ORIGINAL_PRECURSOR_SCAN_NO 9183 CONFIDENCE standard compound; INTERNAL_ID 1187; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9157; ORIGINAL_PRECURSOR_SCAN_NO 9156
5,6-dihydro-6-hydroxy-1-[(2E)-1-oxo-3-(3,4,5-trimethoxyphenyl)-2-propen-1-yl]-2(1H)-Pyridinone
5,6-dihydro-5-hydroxy-1-[(2E)-1-oxo-3-(3,4,5-trimethoxyphenyl)-2-propen-1-yl]-2(1H)-Pyridinone
Gly Gly Asn Ser
Gly Gly Ser Asn
Gly Asn Gly Ser
Gly Asn Ser Gly
Gly Ser Gly Asn
Gly Ser Asn Gly
Asn Gly Gly Ser
Asn Gly Ser Gly
Asn Ser Gly Gly
Ser Gly Gly Asn
Ser Gly Asn Gly
Ser Asn Gly Gly
[[[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxy]-, (E)-Acetic acid
C15H18F3NO4 (333.11878640000003)
11-Hydroxy-11-isopropyl-4-methoxy-8-methyl-10,11-dihydro-6H-oxepino[2,3-d]pyrazino[1,2-a]pyrimidine-6,9(8H)-dione
2-amino-6-(4-fluorophenyl)-3-nitro-4-phenylbenzonitrile
Bisoxatin
C20H15NO4 (333.10010300000005)
A - Alimentary tract and metabolism > A06 - Drugs for constipation > A06A - Drugs for constipation > A06AB - Contact laxatives C78276 - Agent Affecting Digestive System or Metabolism > C29697 - Laxative
tert-Butyl 3-(bromomethyl)-2-oxa-8-azaspiro[4.5]decane-8-carboxylate
C14H24BrNO3 (333.09394540000005)
(R)-2-(((BENZYLOXY)CARBONYL)AMINO)-3-(4-CHLOROPHENYL)PROPANOIC ACID
Thiazolidine, 2-(4-methylphenyl)-3-[(3-methylphenyl)sulfonyl]- (9CI)
C17H19NO2S2 (333.08571539999997)
3-(4-CHLORO-BENZOYLAMINO)-3-(4-METHOXY-PHENYL)-PROPIONIC ACID
(betaS)-beta-[[(tert-Butoxy)carbonyl]amino]-2,4,5-trifluorobenzenebutanoic acid
C15H18F3NO4 (333.11878640000003)
Boc-3-(trifluoromethyl)-D-phenylalanine
C15H18F3NO4 (333.11878640000003)
6,7-Diethoxy-1-phenyl-1,2,3,4-tetrahydroisoquinoline hydrochloride
Boc-(R)-3-Amino-4-(2,4,5-Trifluoro-Phenyl)-Butyric Acid
C15H18F3NO4 (333.11878640000003)
3-AMINO-5-PHENYL-1-(2,2,2-TRIFLUOROETHYL)-1H-BENZO[E][1,4]DIAZEPIN-2(3H)-ONE
3-[(tert-butoxycarbonyl)amino]-3-[3-(trifluoromethyl)phenyl]propanoic acid
C15H18F3NO4 (333.11878640000003)
1-(4-Fluorophenyl)-1-(3-dimethylaminopropyl)-5-chlorophthalane
C19H21ClFNO (333.12956180000003)
2-[3-(4-chlorophenoxy)-5-fluoro-2-methylindol-1-yl]acetic acid
C17H13ClFNO3 (333.0567950000001)
(S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(2-(TRIFLUOROMETHYL)PHENYL)PROPANOIC ACID
C15H18F3NO4 (333.11878640000003)
(S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-(TRIFLUOROMETHYL)PHENYL)PROPANOIC ACID
C15H18F3NO4 (333.11878640000003)
(S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(4-(TRIFLUOROMETHYL)PHENYL)PROPANOIC ACID
C15H18F3NO4 (333.11878640000003)
(R)-BOC-2-(TRIFLUOROMETHYL)-BETA-PHE-OH
C15H18F3NO4 (333.11878640000003)
BOC-(R)-3-AMINO-3-(3-TRIFLUOROMETHYL-PHENYL)-PROPIONICACID
C15H18F3NO4 (333.11878640000003)
Boc-(R)-3-Amino-3-(4-trifluoromethylphenyl)-propionic acid
C15H18F3NO4 (333.11878640000003)
2H-Pyrrol-2-one, 4-acetyl-1-(4-chlorophenyl)-5-cyclohexyl-1,5-dihydro-3-hydroxy-
C18H20ClNO3 (333.1131640000001)
2H-Pyrrol-2-one, 4-acetyl-1-(4-chlorophenyl)-5-cyclohexyl-1,5-dihydro-3-hydroxy-, (5R)-
C18H20ClNO3 (333.1131640000001)
(R)-Duloxetine
C18H20ClNOS (333.0954060000001)
D018377 - Neurotransmitter Agents > D014179 - Neurotransmitter Uptake Inhibitors > D000068760 - Serotonin and Noradrenaline Reuptake Inhibitors D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents D049990 - Membrane Transport Modulators
Ethyl {4-[(4-fluorobenzyl)amino]-2-nitrophenyl}carbamate
Thiazolidine, 2-(2,3-dihydro-1H-phenalen-6-yl)-3-(methylsulfonyl)- (9CI)
C17H19NO2S2 (333.08571539999997)
(2S,3S)-2-AMINO-3-METHOXYBUTANOICACID,98
C18H20ClNO3 (333.1131640000001)
Methyl 1-(2,3-dihydroxypropyl)-4-oxo-3-[(phenylmethyl)oxy]-1,4-dihydro-2-pyridinecarboxylate
Phosphonic acid,[2-[(phenylamino)carbonyl]phenyl]-, diethyl ester (9CI)
3-[(2-chloro-6-fluorophenyl)methyl]-7,7-dimethyl-6,8-dihydro-1H-quinoline-2,5-dione
Duloxetine hydrochloride
C18H20ClNOS (333.0954060000001)
D018377 - Neurotransmitter Agents > D014179 - Neurotransmitter Uptake Inhibitors > D000068760 - Serotonin and Noradrenaline Reuptake Inhibitors D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent D002491 - Central Nervous System Agents > D000700 - Analgesics D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents D049990 - Membrane Transport Modulators
2-((2-TRIFLUOROMETHYLPHENYLAMINO)METHYLENE)MALONIC ACID DIETHYL ESTER
C15H18F3NO4 (333.11878640000003)
N7-METHYL-N2,N7-DIPHENYLTHIAZOLO[5,4-D]PYRIMIDINE-2,7-DIAMINE
C18H15N5S (333.10481100000004)
4-AMINO-5-CHLORO-2-METHOXY-N-(PIPERIDIN-4-YLMETHYL)BENZAMIDE HYDROCHLORIDE
tert-butyl 4-(trifluoromethylsulfonyloxy)piperidine-1-carboxylate
2H-Pyrrol-2-one, 4-acetyl-1-(4-chlorophenyl)-5-cyclohexyl-1,5-dihydro-3-hydroxy-, (5S)-
C18H20ClNO3 (333.1131640000001)
6-BROMO-3-PHENYL-3,4,5,6-TETRAHYDRO-2H-[1,2]BIPYRAZINYL-3-YLAMINE
(E)-N-Methyl-2-[3-(1-methyl-4-piperidinyl)-1H-indol-5-yl]ethenesulfonamide
Dipyrone
N - Nervous system > N02 - Analgesics > N02B - Other analgesics and antipyretics > N02BB - Pyrazolones C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D000893 - Anti-Inflammatory Agents D018501 - Antirheumatic Agents D058633 - Antipyretics
Methanone, [4-(3-chlorophenyl)-1-piperazinyl](3-ethyl-5-methyl-4-isoxazolyl)
C17H20ClN3O2 (333.12439700000004)
2H-Pyrrol-2-one, 4-acetyl-1-(3-chlorophenyl)-5-cyclohexyl-1,5-dihydro-3-hydroxy-
C18H20ClNO3 (333.1131640000001)
1H-PYRROLO[2,3-B]PYRIDINE-5-CARBONITRILE, 4-CHLORO-1-[TRIS(1-METHYLETHYL)SILYL]-
Ethyl 3-(3-amino-4-(methylamino)-N-(pyridin-2-yl)benzamido)propanoate
C15H18F3NO4 (333.11878640000003)
GSK1059615
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2152 - Phosphatidylinositide 3-Kinase Inhibitor C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor
Thiazolidine, 3-(methylsulfonyl)-2-(2,4,5-trimethoxyphenyl)- (9CI)
4-[3-(Methylamino)-1-(2-thienyl)propyl]-1-naphthalenol hydrochloride
C18H20ClNOS (333.0954060000001)
(2E)-2-(HYDROXYIMINO)-N-(3-METHOXYPHENYL)ACETAMIDE
C21H19NOS (333.11872840000007)
3-BROMO-2-(((TERT-BUTYLDIMETHYLSILYL)OXY)METHYL)-6-FLUOROANILINE
(1-(tert-Butoxycarbonyl)-4-(ethoxycarbonyl)-1H-indol-2-yl)boronic acid
C16H20BNO6 (333.13836100000003)
(S)-2-(((BENZYLOXY)CARBONYL)AMINO)-3-(4-CHLOROPHENYL)PROPANOIC ACID
N-(4-TRIFLUOROMETHYL)PHENYL-3-TRIFLUOROMETHYLBENZAMIDE
N-[4-(TRIFLUOROMETHYL)PHENYL]-4-(TRIFLUOROMETHYL)BENZAMIDE
2,5-Diethoxy-4-((4-methylphenyl)thio)nitrobenzene
C17H19NO4S (333.10347340000004)
N-methyl-2-[3-(1-methyl-3,6-dihydro-2H-pyridin-4-yl)-1H-indol-5-yl]ethanesulfonamide
2-Methyl-2-propanyl 4-(4-chloro-1H-pyrrolo[2,3-b]pyridin-2-yl)-3, 6-dihydro-1(2H)-pyridinecarboxylate
C17H20ClN3O2 (333.12439700000004)
Thiazolidine, 2-(4-methylphenyl)-3-[(4-methylphenyl)sulfonyl]- (9CI)
C17H19NO2S2 (333.08571539999997)
2-[N-(2,4-dimethylphenyl)carbamoyl]-3-naphthyl acetate
3-[(TOLUENE-4-SULFONYL)-P-TOLYL-AMINO]-PROPIONIC ACID
C17H19NO4S (333.10347340000004)
ethyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2-benzothiazole-3-carboxylate
C16H20BNO4S (333.1206030000001)
N-(ADAMANTAN-1-YL)-4-BROMOBENZAMIDE
C17H20BrNO (333.07281700000004)
4-(N-[2,4-Diamino-6-pteridinylmethyl]amino)benzoic acid sodium salt
4-(4-Methoxybenzylamino)-5-ethoxycarbonyl-2-Methylthiopyrimidine
C16H19N3O3S (333.11470640000005)
(S)-N-[{3-(4-(3-oxomorpholin-4-yl)phenyl)-2-oxo-1,3-oxazolidin-5-yl}methyl]acetamide
Boc-D-2-Trifluoromethylphenylalanine
C15H18F3NO4 (333.11878640000003)
2-[[(2,4-Difluorophenyl)-2-oxiranyl]methyl]-1H-1,2,4-triazole methanesulfonate
C12H13F2N3O4S (333.05948020000005)
13,14-dihydro-14,14-dimethyl-benz[c]indeno[2,1-a]carbazole
1-(3-Bromo-5-methylpyridin-2-yl)-4-propylpiperazine hydrochloride
C13H21BrClN3 (333.06072760000006)
2-chloro-9-[3-(dimethylamino)propyl]thioxanthen-9-ol
C18H20ClNOS (333.0954060000001)
tert-butyl 3-(4-chlorophenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylate
C17H20ClN3O2 (333.12439700000004)
methyl (2r)-2-[(tert-butoxycarbonyl)amino]-3-(2,4,5-trifluorophenyl)propanoate
C15H18F3NO4 (333.11878640000003)
2-(4-AMINOPHENYL)-6-NITRO-1H-BENZO[DE]ISOQUINOLINE-1,3(2H)-DIONE
2-(3-Bromo-2-oxopropyl)-3-methoxy-1-piperidinecarboxylic acid 2-propenyl ester
C13H20BrNO4 (333.0575620000001)
Golotimod
C308 - Immunotherapeutic Agent > C129820 - Antineoplastic Immunomodulating Agent C274 - Antineoplastic Agent Golotimod (SCV-07), an immunomodulating peptide with antimicrobial activity, significantly increases the efficacy of antituberculosis therapy, stimulates thymic and splenic cell proliferation, and improves macrophage function. Golotimod (SCV-07) inhibits STAT3 signaling and modulates the duration and severity of oral mucositis in animal models that received radiation or a combination of radiation and Cisplatin. Golotimod (SCV-07) is also a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2)[1][2][3].
4-(5,11-Dioxo-5H-indeno[1,2-C]isoquinolin-6(11H)-YL)butanoate
C20H15NO4 (333.10010300000005)
Picibanil
C308 - Immunotherapeutic Agent > C210 - Immunoadjuvant > C2141 - Chemo Immunostimulant Adjuvant D000970 - Antineoplastic Agents C2140 - Adjuvant
(11-Amino-7-methoxy-12-methyl-10,13-dioxo-2,5-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),11-dien-8-yl)methyl acetate
N-(4-chloro-2-fluorophenyl)-6,7-dimethoxyquinazolin-4-amine
(RS)-1-(2-amino-2-carboxyethyl)-3-(2-carboxybenzyl)pyrimidine-2,4-dione
ethyl 2-(furan-2-carboxamido)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylate
C17H19NO4S (333.10347340000004)
2-[4-(4-Fluorobenzoyl)phenyl]-2-(4-fluorophenyl)acetonitrile
C21H13F2NO (333.09651520000006)
Ethanamine, 2-((R)-(4-bromophenyl)phenylmethoxy)-N,N-dimethyl-
C17H20BrNO (333.07281700000004)
3-(1-Benzotriazolylmethyl)-6-phenyl-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole
1-Butyl-4,6-dimethyl-3-(2-methylphenyl)sulfonyl-2-pyridinone
2-{3-nitroanilino}-N-({5-nitro-2-furyl}methylene)acetohydrazide
N-[3-(7-methyl-2-imidazo[1,2-a]pyridinyl)phenyl]-2-thiophenecarboxamide
C19H15N3OS (333.09357800000004)
Ethanamine, 2-((S)-(4-bromophenyl)phenylmethoxy)-N,N-dimethyl-
C17H20BrNO (333.07281700000004)
1-(5-Chloro-2,4-Dimethoxyphenyl)-3-(5-Cyanopyrazin-2-Yl)urea
C14H12ClN5O3 (333.06286320000004)
d-[3-Hydroxy-2-methyl-5-phosphonooxymethyl-pyridin-4-ylmethyl]-n,o-cycloserylamide
6900-99-8
C20H15NO4 (333.10010300000005)
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents D000970 - Antineoplastic Agents
3-(6H-benzo[c][1]benzothiepin-11-ylidene)-8-methyl-8-azabicyclo[3.2.1]octane
N - Nervous system > N04 - Anti-parkinson drugs > N04A - Anticholinergic agents > N04AA - Tertiary amines
1-Tert-butyl-3-[(3-chloro-4-fluorophenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-amine
(2R)-2,3-dihydroxypropyl (1S,2R,3R,4S,5S,6R)-2,3,4,5,6-pentahydroxycyclohexyl phosphate
5,7-diacetamido-3,5,7,9-tetradeoxy-L-glycero-D-galacto-non-2-ulosonate
5,7-diacetamido-3,5,7,9-tetradeoxy-D-glycero-D-talo-non-2-ulosonate
5,7-diacetamido-3,5,7,9-tetradeoxy-L-glycero-D-talo-non-2-ulosonate
5,7-bis(acetamido)-3,5,7,9-tetradeoxy-L-glycero-beta-L-manno-2-nonulopyranosonic acid
Oxonorfloxacin
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D024841 - Fluoroquinolones
N-bicyclo[2.2.1]hept-2-yl-2-[(2,3-dimethoxyphenyl)methylene]-1-hydrazinecarbothioamide
Leu-Asp-Ser
C13H23N3O7 (333.15359279999996)
A tripeptide composed of L-leucine, L-aspartic acid and L-serine joined in sequence by peptide linkages.
1-[5-[4-(Methylthio)phenyl]-2-thiazolyl]-4-piperidinecarboxamide
7,8-Dimethoxy-1,5-dimethyl-3-phenylpyrazolo[3,4-c]isoquinoline
N-cyclopentyl-2-[[1-(2-methoxyphenyl)-5-tetrazolyl]thio]acetamide
5-(2-Furanyl)-3-[2-methoxy-6-(4-methylphenyl)-3-pyridinyl]-1,2,4-oxadiazole
C19H15N3O3 (333.11133600000005)
N-[[5-(2,4-difluorophenyl)-1H-pyrazol-4-yl]methyl]-1-(3-thiophenyl)-2-propanamine
C17H17F2N3S (333.11111860000005)
Glu-Glu-Gly
A tripeptide composed of two L-glutamic acid and one glycine residues joined in sequence.
(2S)-2-{[(2-benzyl-5-oxo-1,3-oxazol-4(5H)-ylidene)methyl]amino}-3-methyl-3-sulfanylbutanoate
3-methyl-N,6-diphenyl-2-imidazo[2,1-b]thiazolecarboxamide
C19H15N3OS (333.09357800000004)
2-[2-[[1-(4-Chlorophenyl)-4-pyrazolo[3,4-d]pyrimidinyl]amino]ethoxy]ethanol
C15H16ClN5O2 (333.09924659999996)
2-[4-(4-Chloro-2-nitrophenyl)-1-piperazinyl]phenol
C16H16ClN3O3 (333.08801359999995)
1-(3-Chlorophenyl)-3-[2-(dimethylamino)-2-phenylethyl]thiourea
C17H20ClN3S (333.1066390000001)
3-Pyridinecarboxylic acid [2-(2-furanyl)-4-oxo-1-benzopyran-3-yl] ester
N-(4-chloro-2-fluorophenyl)-3-(methoxymethyl)-2-benzofurancarboxamide
C17H13ClFNO3 (333.0567950000001)
N-[2-(1H-benzimidazol-2-yl)phenyl]-2-thiophen-2-ylacetamide
C19H15N3OS (333.09357800000004)
2-(1H-benzimidazol-2-ylthio)-N-(5-propyl-1,3,4-thiadiazol-2-yl)acetamide
1-(2-Benzofuranyl)-2-[(4-methyl-2-quinolinyl)thio]ethanone
C20H15NO2S (333.08234500000003)
7-methoxy-N-(3-pyridinylmethyl)-2-furo[2,3-b]quinolinecarboxamide
C19H15N3O3 (333.11133600000005)
[2-[3-(4-Methylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]-(1-pyrrolidinyl)methanone
1-(3-Methylphenyl)-3-[[oxo-(5-propyl-3-thiophenyl)methyl]amino]thiourea
2-Chloro-5-methyl-1-oxo-3-phenyl-4-pyrido[1,2-a]benzimidazolecarbonitrile
2-[[5-(4-Fluorophenyl)-1-methyl-2-imidazolyl]thio]-1-(1-piperidinyl)ethanone
C17H20FN3OS (333.13110420000004)
2-[(7-Ethyl-[1,3]dioxolo[4,5-g]quinolin-6-yl)thio]acetic acid propan-2-yl ester
C17H19NO4S (333.10347340000004)
naphthalen-2-yl (2S)-2-acetamido-3-phenylpropanoate
N-(1-cyano-4-piperidinyl)-4-(trifluoromethyl)benzenesulfonamide
C13H14F3N3O2S (333.07587800000005)
1-[1-(1-Ethyl-3-methyl-4-pyrazolyl)ethyl]-3-(3-nitrophenyl)thiourea
(2E,5Z)-2-(3,3-dimethyl-2-oxo-butylidene)-5-[(3-hydroxy-4-methoxy-phenyl)methylene]thiazolidin-4-one
C17H19NO4S (333.10347340000004)
(2,3,4-Triacetyloxy-5-amino-5-oxopentyl) acetate
C13H19NO9 (333.10597640000003)
1-[4-[4-(Methylthio)phenyl]-2-thiazolyl]-4-piperidinecarboxamide
(7R)-7-[4-(6-oxo-1,6-dihydropyrimidin-4-yl)piperidine-1-carbonyl]-1,3-diazepane-2,4-dione
(2R,3R,4S)-4-(hydroxymethyl)-3-[4-[(E)-prop-1-enyl]phenyl]-1-(pyridine-3-carbonyl)azetidine-2-carbonitrile
(2S,3R,4S)-4-(hydroxymethyl)-3-[4-[(E)-prop-1-enyl]phenyl]-1-(pyridine-3-carbonyl)azetidine-2-carbonitrile
(2S,3S,4S)-4-(hydroxymethyl)-3-[4-[(E)-prop-1-enyl]phenyl]-1-(pyridine-3-carbonyl)azetidine-2-carbonitrile
(2S,3S,4R)-4-(hydroxymethyl)-3-[4-[(E)-prop-1-enyl]phenyl]-1-(pyridine-3-carbonyl)azetidine-2-carbonitrile
(6S,7S,8S)-8-(hydroxymethyl)-7-[4-[2-(3-pyridinyl)ethynyl]phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6S,7R,8S)-8-(hydroxymethyl)-7-[4-[2-(3-pyridinyl)ethynyl]phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
4-[4-[(6S,7S,8R)-8-(hydroxymethyl)-2-oxo-1,4-diazabicyclo[4.2.0]octan-7-yl]phenyl]benzonitrile
4-[4-[(6S,7R,8S)-8-(hydroxymethyl)-2-oxo-1,4-diazabicyclo[4.2.0]octan-7-yl]phenyl]benzonitrile
4-[4-[(6S,7R,8R)-8-(hydroxymethyl)-2-oxo-1,4-diazabicyclo[4.2.0]octan-7-yl]phenyl]benzonitrile
(2R,3R,4R)-4-(hydroxymethyl)-3-[4-[(E)-prop-1-enyl]phenyl]-1-(pyridine-3-carbonyl)azetidine-2-carbonitrile
(6S,7S,8R)-8-(hydroxymethyl)-7-[4-[2-(3-pyridinyl)ethynyl]phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6R,7R,8S)-8-(hydroxymethyl)-7-[4-[2-(3-pyridinyl)ethynyl]phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
4-[4-[(6S,7S,8S)-8-(hydroxymethyl)-2-oxo-1,4-diazabicyclo[4.2.0]octan-7-yl]phenyl]benzonitrile
4-[4-[(6R,7S,8S)-8-(hydroxymethyl)-2-oxo-1,4-diazabicyclo[4.2.0]octan-7-yl]phenyl]benzonitrile
4-[4-[(6R,7R,8S)-8-(hydroxymethyl)-2-oxo-1,4-diazabicyclo[4.2.0]octan-7-yl]phenyl]benzonitrile
4-[4-[(6R,7R,8R)-8-(hydroxymethyl)-2-oxo-1,4-diazabicyclo[4.2.0]octan-7-yl]phenyl]benzonitrile
4-[4-[(6R,7S,8R)-8-(hydroxymethyl)-2-oxo-1,4-diazabicyclo[4.2.0]octan-7-yl]phenyl]benzonitrile
(2S)-5-(methylamino)-2-phenyl-4-[3-(trifluoromethyl)phenyl]furan-3(2H)-one
N-[2-[(2Z)-2-[(2-hydroxy-3-methoxyphenyl)methylidene]hydrazinyl]-2-oxoethyl]thiophene-2-carboxamide
7-[[(2S)-2-aminopropyl]amino]-1-cyclopropyl-6-fluoro-5-methyl-4-oxoquinoline-3-carboxylic acid
C17H20FN3O3 (333.14886220000005)
Dibutyl 2-(N-trifluoroacetylamino)ethylphosphonate
2-Trimethylsilyloxy-4-quinolinecarboxylicacid trimethylsilyl ester
5-Tert-butyl-2,3-dimethoxycarbonyl-5,6-dihydropyrrolo(1,2-D)(1,2,4)triazocin-6-one
Chelerythrine
C20H15NO4 (333.10010300000005)
Norchelerythrine is a benzophenanthridine alkaloid. Norchelerythrine is a natural product found in Zanthoxylum beecheyanum, Zanthoxylum scandens, and other organisms with data available. D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents D000970 - Antineoplastic Agents
bromazine
C17H20BrNO (333.07281700000004)
R - Respiratory system > R06 - Antihistamines for systemic use > R06A - Antihistamines for systemic use > R06AA - Aminoalkyl ethers C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist
Oglufanide
C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor C308 - Immunotherapeutic Agent Oglufanide (H-Glu-Trp-OH) is a dipeptide immunomodulator isolated from calf thymus. Oglufanide inhibits vascular endothelial growth factor (VEGF). Oglufanide can stimulate the immune response to hepatitic C virus (HCV) and intracellular bacterial infections. Oglufanide shows antitumor and anti-angiogenesis activities[1][2][3]. Oglufanide (H-Glu-Trp-OH) is a dipeptide immunomodulator isolated from calf thymus. Oglufanide inhibits vascular endothelial growth factor (VEGF). Oglufanide can stimulate the immune response to hepatitic C virus (HCV) and intracellular bacterial infections. Oglufanide shows antitumor and anti-angiogenesis activities[1][2][3].
7-demethylmitomycin B(2-)
A phenolate anion obtained by removal of two protons from position C-8 and O-6 of 7-demethylmitomycin B. It is the major microspecies at pH 7.3 (according to Marvin v 6.2.0.).
7-demethylmitomycin A(2-)
A phenolate anion obtained by removal of two protons from position C-8 and O-6 of 7-demethylmitomycin A. It is the major microspecies at pH 7.3 (according to Marvin v 6.2.0.).
1-(sn-glycero-3-O-phosphonato)-1D-myo-inositol
An inositol phosphate oxoanion obtained by deprotonation of the free phosphate OH group of 1-(sn-glycero-3-phospho)-1D-myo-inositol; major species at pH 7.3.
Glu-TRP
A dipeptide composed of L-glutamic acid and L-tryptophan joined by a peptide linkage.
B-Raf IN 15
C19H15N3OS (333.09357800000004)
B-Raf IN 15 (Compound 7) is a BRAF inhibitor. B-Raf IN 15 inhibits BRAF WT and BRAF V600E with IC50s of 2.0 and 0.8 μM. B-Raf IN 15 can be used for the research of cancer[1].
CP-409092 (hydrochloride)
C17H20ClN3O2 (333.12439700000004)
CP-409092 hydrochloride is a partial agonist of GABAA receptor, with anti-anxiety activity[1].
7-methoxy-6'-methyl-3'-oxaspiro[isoindole-1,2'-tricyclo[6.3.1.0⁴,¹²]dodecane]-1'(12'),4',6',8',10'-pentaene-3,11'-diol
C20H15NO4 (333.10010300000005)
(1s,13r,15r,16s,18r)-9-methoxy-5,7,17-trioxa-12-azahexacyclo[10.6.2.0¹,¹³.0²,¹⁰.0⁴,⁸.0¹⁶,¹⁸]icosa-2(10),3,8-triene-11,15-diol
3-benzyl-6-(1h-indol-3-ylmethyl)-3,6-dihydropyrazine-2,5-diol
15,16-dimethoxy-11-azapentacyclo[9.6.2.0²,⁷.0⁸,¹⁹.0¹⁴,¹⁸]nonadeca-1(18),2(7),3,5,8(19),14,16-heptaene-9,10-dione
C20H15NO4 (333.10010300000005)
(3s,6s)-6-(1-hydroxyethyl)-3-(1h-indol-3-ylmethyl)-3-(methylsulfanyl)-6h-pyrazine-2,5-diol
C16H19N3O3S (333.11470640000005)
2-amino-1,7-dihydroxy-3,9-dimethoxy-1-methylbenzo[c]chromene-4,6-dione
C16H15NO7 (333.08484799999997)
(3s,6s)-3-benzyl-6-(1h-indol-3-ylmethyl)-3,6-dihydropyrazine-2,5-diol
11-hydroxy-8-(1h-indol-3-yl)-3,9-diazatricyclo[8.4.0.0³,⁷]tetradeca-1(14),10,12-trien-2-one
(1r)-19-[(1s)-1-hydroxyethyl]-3,13,17-triazapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-2(10),4,6,8,15(20),16,18-heptaen-14-one
{3-[(2r,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-2,6-dioxopyrimidin-1-yl}sulfanylcarbamic acid
C11H15N3O7S (333.06306800000004)
n-[(1z)-2-[(4as,6s,8ar)-6-chloro-5,5,8a-trimethyl-3,4,4a,6,7,8-hexahydronaphthalen-2-yl]ethenyl]-1-chloromethanecarbonimidoyl chloride
C16H22Cl3N (333.08177420000004)
n-[(1e)-2-[(4ar,6s,8ar)-6-chloro-5,5,8a-trimethyl-3,4,4a,6,7,8-hexahydronaphthalen-2-yl]ethenyl]-1-chloromethanecarbonimidoyl chloride
C16H22Cl3N (333.08177420000004)
15-methyl-5,7,18,20-tetraoxa-24-azahexacyclo[11.11.0.0²,¹⁰.0⁴,⁸.0¹⁴,²².0¹⁷,²¹]tetracosa-1(13),2,4(8),9,11,14(22),15,17(21)-octaene
C20H15NO4 (333.10010300000005)
methyl 1,2,2-trimethoxy-3-methyl-8-oxocyclobuta[b]quinoline-1-carboxylate
19-(1-hydroxyethyl)-3,13,17-triazapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-2(10),4,6,8,15(20),16,18-heptaen-14-one
(3s)-3-{[(2s)-2-amino-1-hydroxy-4-methylpentylidene]amino}-3-{[(1s)-1-carboxy-2-hydroxyethyl]-c-hydroxycarbonimidoyl}propanoic acid
C13H23N3O7 (333.15359279999996)
(1s,11r,13r,15r,16s,18r)-9-methoxy-5,7,17-trioxa-12-azahexacyclo[10.6.2.0¹,¹³.0²,¹⁰.0⁴,⁸.0¹⁶,¹⁸]icosa-2(10),3,8-triene-11,15-diol
(2e)-3-({5,6-dihydroxy-3-methyl-2-oxo-4-[(1e)-prop-1-en-1-yl]-1-benzofuran-3-yl}-c-hydroxycarbonimidoyl)prop-2-enoic acid
C16H15NO7 (333.08484799999997)
2,18-dihydroxy-7-methoxy-13-methyl-10-azapentacyclo[9.7.1.0²,¹⁰.0³,⁸.0¹⁵,¹⁹]nonadeca-1(19),3(8),4,6,11,13,15,17-octaen-9-one
C20H15NO4 (333.10010300000005)
(4z,7r)-6-hydroxy-7-methyl-4-(phenylmethylidene)-15-oxa-2,5,8-triazatricyclo[8.5.0.0³,⁸]pentadeca-1(10),2,5,11,13-pentaen-9-one
C19H15N3O3 (333.11133600000005)
1-chloro-n-[2-(6-chloro-5,5,8a-trimethyl-3,4,4a,6,7,8-hexahydronaphthalen-2-yl)ethenyl]methanecarbonimidoyl chloride
C16H22Cl3N (333.08177420000004)
10b-hydroxy-7,8-dimethoxy-2,2,6-trimethylpyrano[3,2-c]quinoline-3,5-dione
(7s,8s)-11-hydroxy-8-(1h-indol-3-yl)-3,9-diazatricyclo[8.4.0.0³,⁷]tetradeca-1(14),10,12-trien-2-one
(1z,4r)-3,10-dihydroxy-4-methyl-1-(phenylmethylidene)-4h-pyrazino[2,1-b]quinazolin-6-one
C19H15N3O3 (333.11133600000005)
{3-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-2,6-dioxopyrimidin-1-yl}sulfanylcarbamic acid
C11H15N3O7S (333.06306800000004)
(2s)-2-amino-3-[4-(3,4,5-trihydroxybenzoyloxy)phenyl]propanoic acid
C16H15NO7 (333.08484799999997)
(1r)-19-[(1r)-1-hydroxyethyl]-3,13,17-triazapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-2(10),4,6,8,15(20),16,18-heptaen-14-one
15,16-dimethoxy-5,7-dioxa-21-azapentacyclo[11.8.0.0²,¹⁰.0⁴,⁸.0¹⁴,¹⁹]henicosa-1(13),2(10),3,8,11,14(19),15,17,20-nonaene
C20H15NO4 (333.10010300000005)
6-(1-hydroxyethyl)-3-(1h-indol-3-ylmethyl)-3-(methylsulfanyl)-6h-pyrazine-2,5-diol
C16H19N3O3S (333.11470640000005)
5,7,18,20-tetraoxa-24-azahexacyclo[11.11.0.0²,¹⁰.0⁴,⁸.0¹⁴,²².0¹⁷,²¹]tetracosa-1(13),2(10),3,8,11,14(22),15,17(21),23-nonaen-23-ol
17-methoxy-21-methyl-5,7-dioxa-21-azapentacyclo[11.8.0.0²,¹⁰.0⁴,⁸.0¹⁴,¹⁹]henicosa-1(13),2,4(8),9,11,14,16,19-octaen-18-one
C20H15NO4 (333.10010300000005)
8,9-dimethoxy-4,6-dioxa-15-azapentacyclo[11.8.0.0²,¹⁰.0³,⁷.0¹⁶,²¹]henicosa-1(13),2(10),3(7),8,11,14,16(21),17,19-nonaene
C20H15NO4 (333.10010300000005)
12-methyl-5,7,17,19-tetraoxa-12-azahexacyclo[11.11.0.0²,¹⁰.0⁴,⁸.0¹⁴,²².0¹⁶,²⁰]tetracosa-1(13),2,4(8),9,14,16(20),21,23-octaene
C20H15NO4 (333.10010300000005)
3-{[5,6-dihydroxy-3-methyl-2-oxo-4-(prop-1-en-1-yl)-1-benzofuran-3-yl]-c-hydroxycarbonimidoyl}prop-2-enoic acid
C16H15NO7 (333.08484799999997)
18-hydroxy-17-methoxy-3,13,21-triazapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-1(21),2(10),4,6,8,15,17,19-octaen-14-one
C19H15N3O3 (333.11133600000005)
(11s,12r)-12-hydroxy-11-methoxy-3,13,21-triazapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-1(21),2(10),4,6,8,15,17,19-octaen-14-one
C19H15N3O3 (333.11133600000005)
methyl (2s)-3-{[(2r)-2-hydroxy-3-methoxy-3-oxopropyl]sulfanyl}-2-[(3r)-3-methyl-2,5-dioxopyrrolidin-1-yl]propanoate
17-methoxy-21-methyl-5,7-dioxa-21-azapentacyclo[11.8.0.0²,¹⁰.0⁴,⁸.0¹⁴,¹⁹]henicosa-1(13),2,4(8),9,11,14,17,19-octaen-16-one
C20H15NO4 (333.10010300000005)
methyl (1s,5s)-4-hydroxy-6-[4-(methoxycarbonyl)phenyl]-8-methyl-3,6,8-triazabicyclo[3.2.1]oct-3-ene-5-carboxylate
methyl 4-hydroxy-6-[4-(methoxycarbonyl)phenyl]-8-methyl-3,6,8-triazabicyclo[3.2.1]oct-3-ene-5-carboxylate
methyl 2-hydroxy-3-{[3-methoxy-2-(3-methyl-2,5-dioxopyrrolidin-1-yl)-3-oxopropyl]sulfanyl}propanoate
methyl 2-[(3r,4s)-4,11-dihydroxy-3-methoxy-3,7-dimethyl-2-oxa-6-azatricyclo[7.3.1.0⁵,¹³]trideca-1(13),5,7,9,11-pentaen-4-yl]acetate
(2s)-2-{[hydroxy(3,4,5-trihydroxyphenyl)methylidene]amino}-3-(4-hydroxyphenyl)propanoic acid
C16H15NO7 (333.08484799999997)
7-(3-hydroxy-3-methyl-2-oxobutyl)-6-methoxy-9-methyl-2h-[1,3]dioxolo[4,5-h]quinolin-8-one
9-methoxy-5,7,17-trioxa-12-azahexacyclo[10.6.2.0¹,¹³.0²,¹⁰.0⁴,⁸.0¹⁶,¹⁸]icosa-2(10),3,8-triene-11,15-diol
16,17-dimethoxy-5,7-dioxa-21-azapentacyclo[11.8.0.0²,¹⁰.0⁴,⁸.0¹⁴,¹⁹]henicosa-1(13),2(10),3,8,11,14(19),15,17,20-nonaene
C20H15NO4 (333.10010300000005)
3,10-dihydroxy-4-methyl-1-(phenylmethylidene)-4h-pyrazino[2,1-b]quinazolin-6-one
C19H15N3O3 (333.11133600000005)
(1r)-2-amino-1,7-dihydroxy-3,9-dimethoxy-1-methylbenzo[c]chromene-4,6-dione
C16H15NO7 (333.08484799999997)
(2e)-3-{[(3s)-5,6-dihydroxy-3-methyl-2-oxo-4-[(1e)-prop-1-en-1-yl]-1-benzofuran-3-yl]-c-hydroxycarbonimidoyl}prop-2-enoic acid
C16H15NO7 (333.08484799999997)
4-methoxy-6'-methyl-3'-oxaspiro[isoindole-1,2'-tricyclo[6.3.1.0⁴,¹²]dodecane]-1'(12'),4',6',8',10'-pentaene-3,11'-diol
C20H15NO4 (333.10010300000005)
(1r,5's,6'r,7'ar)-5',6,6'-trihydroxy-5-methoxy-1'-methyl-3',5',6',7'a-tetrahydro-2'h-spiro[2-benzofuran-1,7'-indol]-3-one
6-hydroxy-7-methyl-4-(phenylmethylidene)-15-oxa-2,5,8-triazatricyclo[8.5.0.0³,⁸]pentadeca-1(10),2,5,11,13-pentaen-9-one
C19H15N3O3 (333.11133600000005)